---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Brentuximab Vedotin - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/brentuximabvedotin
version: v1
---

# Brentuximab Vedotin - NCI

# Brentuximab Vedotin

Placeholder slot

(bren-TUK-sih-mab veh-DOH-tin)

This page contains brief information about brentuximab vedotin
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Adcetris

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3904f8dd-1aef-3490-e48f-bd55f32ed67f&audience=consumer)

## Use in Cancer

Brentuximab vedotin
is approved to treat:

- **[Anaplastic large cell lymphoma](/Common/PopUps/popDefinition.aspx?id=45552&version=Patient&language=English)**. Brentuximab vedotin is used in:
- Adults whose cancer is [systemic](/Common/PopUps/popDefinition.aspx?id=45921&version=Patient&language=English) and has not gotten better after treatment with [combination chemotherapy](/Common/PopUps/popDefinition.aspx?id=45650&version=Patient&language=English).
- Adults whose cancer has not been treated. Brentuximab vedotin is given with [cyclophosphamide](/Common/PopUps/popDefinition.aspx?id=45253&version=Patient&language=English), [doxorubicin hydrochloride](/Common/PopUps/popDefinition.aspx?id=560140&version=Patient&language=English), and [prednisone](/Common/PopUps/popDefinition.aspx?id=45492&version=Patient&language=English).
- **Classic [Hodgkin lymphoma](/Common/PopUps/popDefinition.aspx?id=270800&version=Patient&language=English).** Brentuximab vedotin is used:
- After an [autologous stem cell transplant](/Common/PopUps/popDefinition.aspx?id=270733&version=Patient&language=English) (ASCT) in adults who have a high risk that the cancer will come back or get worse.
- In adults whose cancer has not gotten better after an ASCT. Brentuximab vedotin is also used in adults whose cancer has not gotten better after at least two treatments with combination chemotherapy and who cannot receive an ASCT.
- With doxorubicin hydrochloride, [vinblastine sulfate](/Common/PopUps/popDefinition.aspx?id=637631&version=Patient&language=English), and [dacarbazine](/Common/PopUps/popDefinition.aspx?id=45260&version=Patient&language=English) in adults with [stage III](/Common/PopUps/popDefinition.aspx?id=45897&version=Patient&language=English) or [stage IV Hodgkin lymphoma](/Common/PopUps/popDefinition.aspx?id=45898&version=Patient&language=English) whose cancer has not been treated.
- With doxorubicin hydrochloride, [vincristine sulfate](/Common/PopUps/popDefinition.aspx?id=615324&version=Patient&language=English), [etoposide](/Common/PopUps/popDefinition.aspx?id=45189&version=Patient&language=English), prednisone, and [cyclophosphamide](/Common/PopUps/popDefinition.aspx?id=45253&version=Patient&language=English) in children aged 2 years and older whose cancer has not been treated and who have a high risk that the cancer will come back or get worse.
- **[Cutaneous](/Common/PopUps/popDefinition.aspx?id=46112&version=Patient&language=English) anaplastic large cell lymphoma** that is [primary](/Common/PopUps/popDefinition.aspx?id=748354&version=Patient&language=English). Brentuximab vedotin is used in adults who have received other [systemic therapy](/Common/PopUps/popDefinition.aspx?id=45922&version=Patient&language=English).
- **[Diffuse large B-cell lymphoma](/Common/PopUps/popDefinition.aspx?id=428286&version=Patient&language=English)** or **[high-grade](/Common/PopUps/popDefinition.aspx?id=45710&version=Patient&language=English) [B-cell lymphoma](/Common/PopUps/popDefinition.aspx?id=444967&version=Patient&language=English).** Brentuximab vedotin is used with [lenalidomide](/Common/PopUps/popDefinition.aspx?id=393761&version=Patient&language=English) and [rituximab](/Common/PopUps/popDefinition.aspx?id=45525&version=Patient&language=English) in adults whose cancer has come back or didnâ€™t respond to at least two types of systemic therapy and cannot be treated with an ASCT or [CAR T-cell therapy](/Common/PopUps/popDefinition.aspx?id=771302&version=Patient&language=English).
- **[Mycosis fungoides](/Common/PopUps/popDefinition.aspx?id=45794&version=Patient&language=English)** (a type of [cutaneous T-cell lymphoma](/Common/PopUps/popDefinition.aspx?id=46771&version=Patient&language=English)). Brentuximab vedotin is used in adults whose cancer has the [CD30 protein](/Common/PopUps/popDefinition.aspx?id=796822&version=Patient&language=English) and who have received other systemic therapy.
- **[Peripheral T-cell lymphoma](/Common/PopUps/popDefinition.aspx?id=405873&version=Patient&language=English)** that has the CD30 protein. Brentuximab vedotin is given with cyclophosphamide, doxorubicin hydrochloride, and prednisone in adults.

Brentuximab vedotin
is also being studied in the treatment of other conditions and types of
cancer.

## More About Brentuximab Vedotin

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/530758) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Brentuximab Vedotin](https://medlineplus.gov/druginfo/meds/a611052.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents](https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-brentuximab-children-hodgkin-lymphoma)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Brentuximab Vedotin](https://www.cancer.gov/research/participate/clinical-trials/intervention/C66944) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
